TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A phase III study found that 86% to 90% of children with enthesitis-related arthritis or juvenile psoriatic arthritis receiving ixekizumab met the trial’s treatment-response definition at week 16. The findings add to interest in biologics for juvenile spondyloarthritis, but pediatric treatment choices remain limited, long-term evidence is incomplete, and safety and off-label use require discussion with clinicians.
A phase III trial found that ixekizumab met its treatment-response threshold at week 16 in 90% of biologic-naive and 86% of biologic-experienced participants with enthesitis-related arthritis or juvenile psoriatic arthritis. The results add to evidence for biologic treatment of juvenile spondyloarthritis, but do not establish long-term benefit or resolve questions about which drug is best for children.
The 101-participant COSPIRIT-JIA trial tested ixekizumab, an interleukin-17 inhibitor marketed as Taltz. Its primary response measure was a juvenile idiopathic arthritis-ACR 30 response: at least 30% improvement in three of six core measures, with no more than one of the remaining measures worsening by more than 30%. The reported percentages describe participants meeting that trial definition at week 16; they do not mean that the disease was cured or that every symptom improved.
The source report said ixekizumab was well tolerated and effective in the study, and that its safety profile in children appeared similar to the adult profile. Those are findings from the trial, not a guarantee of safety for every patient. The results could support consideration of a pediatric indication beyond the drug’s existing plaque psoriasis use, but the supplied report does not say that regulators have approved such an expanded indication.
Secukinumab (Cosentyx) was described in the report as the only FDA-approved biologic for enthesitis-related arthritis in children. With relatively few biologics officially available for juvenile disease, clinicians also use biologics and targeted synthetic disease-modifying drugs off label. The report notes a 2026 American College of Rheumatology guideline update recommending a TNF or IL-17 inhibitor as an initial biologic after first-line therapy with nonsteroidal anti-inflammatory drugs, while offering no general preference for a particular drug in either class.
Earlier Treatment, Long-Term Questions
The case for studying biologics in children is not limited to reducing symptoms now. Juvenile spondyloarthritis can develop over time: spine or sacroiliac-joint involvement may appear five to 10 years after an enthesitis-related arthritis diagnosis. Researchers and clinicians are interested in whether earlier control of inflammation could help limit later complications, including progressive axial disease and hip damage.
That potential benefit remains a rationale for research, not a proven outcome of the ixekizumab trial. The 16-week response figures do not show whether treatment prevents radiographic progression, reduces the need for hip replacement, or changes disease over many years. Robert Colbert, a pediatric rheumatologist at the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases, told MedPage Today that biologics targeting TNF and IL-17A have changed spondyloarthritis treatment and long-term outcomes. The extent to which adult findings translate to children needs further study.
For families, the development adds evidence to treatment discussions in a field with limited pediatric options. It also makes the balance of expected benefit, possible harms, and uncertainty central to decisions, especially when a medicine is being used off label.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Hyperice Normatec Elite Wireless Compression Boots, Standard Size
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
Juvenile Disease Can Emerge Gradually
Juvenile and adult spondyloarthritis are related inflammatory conditions, but they do not always look the same. The source report describes juvenile disease as often involving episodic mild-to-moderate hip or peripheral-joint flares, with less spinal involvement early on. It identifies enthesitis-related arthritis as a juvenile form related to ankylosing spondylitis, and juvenile psoriatic arthritis as part of the same broader disease family.
Early identification is difficult, according to Colbert, and delayed recognition can postpone treatment. New classification criteria for axial juvenile spondyloarthritis may help identify cases, but they do not remove the diagnostic challenge. The report cites studies finding that as many as 40% of children with enthesitis-related arthritis may go on to develop juvenile ankylosing spondylitis; it also says up to 20% of people with spondyloarthritis have disease onset in childhood. These estimates come from the cited studies and should not be read as an individual child’s forecast.
Available treatment guidance reflects evidence gaps. The 2026 ACR update includes many conditional recommendations because the evidence was rated very low. Dax Rumsey, a physician at Stollery Children’s Hospital and the University of Alberta, told MedPage Today that clinicians generally choose a TNF inhibitor first when there is no major contraindication, while the guideline itself does not name a preferred agent.
“Overall, the biologics have been game-changing in the treatment of juvenile SpA.”
— Dax Rumsey, MD, MSc, of Stollery Children’s Hospital and the University of Alberta, speaking to MedPage Today
Approval and Long-Term Safety Remain Open
The report does not provide a regulatory decision on ixekizumab for juvenile enthesitis-related arthritis or juvenile psoriatic arthritis. It also does not give detailed trial results beyond the week-16 response proportions and the reported safety characterization. Long-term outcomes, including whether early treatment prevents later axial damage, remain unknown from the information supplied.
Safety needs continued attention. The report associates TNF inhibitors with infection-related complications and increased risk of autoimmune disease; IL-17 inhibitors have been linked to infections, particularly candidiasis, inflammatory bowel disease, and mental health conditions. It says secukinumab’s safety in the JUNIPERA phase III trial was comparable to prior reports in adults, but longer-term safety data are more extensive in adults than in children. The available source material does not specify rates for these risks in the pediatric trials or settle how they compare across drugs.
It is also unclear how often off-label biologic use occurs in children, which patients are most likely to benefit, and whether one drug class is preferable for particular juvenile disease patterns. The trial percentages alone cannot answer those questions.
Regulatory Review and Follow-Up Data
The next developments to watch are any regulatory review of ixekizumab for pediatric indications, publication of full trial data, and longer follow-up on effectiveness and safety. Until then, treatment decisions remain individualized and should account for a child’s symptoms, disease features, other health conditions, and response to earlier treatment.
Colbert told MedPage Today that pre-screening and monitoring are part of biologic use, while Rumsey underscored the need for additional research for patients who do not respond to existing options. The source report does not provide a date for a regulatory decision or further trial milestones, so both remain uncertain.
Key Questions
What did the ixekizumab trial find?
In the 101-participant phase III COSPIRIT-JIA trial, 90% of biologic-naive and 86% of biologic-experienced participants met the defined juvenile idiopathic arthritis-ACR 30 treatment-response threshold at week 16.
Does the trial show that ixekizumab is approved for children?
No pediatric approval is reported in the supplied article. The findings may support consideration of an expanded indication, but the article does not report a regulatory decision.
The report identifies secukinumab (Cosentyx) as the only FDA-approved biologic for enthesitis-related arthritis in children at the time described. Other medicines may be used off label under a clinician’s care.
What safety concerns are reported?
The article describes infection-related and autoimmune risks associated with TNF inhibitors, and infections, inflammatory bowel disease, and mental health conditions associated with IL-17 inhibitors. It says clinicians use screening and monitoring, and that IL-17A inhibitors are avoided in patients with inflammatory bowel disease.
Does early biologic treatment prevent spinal damage?
That is a proposed potential benefit, not an outcome established by the 16-week trial. Whether early treatment prevents long-term axial progression or later complications in children remains a research question.
Source: medpagetoday.com
